• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

米非司酮治疗与战斗相关创伤后应激障碍的初步研究。

A Pilot Study of Mifepristone in Combat-Related PTSD.

作者信息

Golier Julia A, Caramanica Kimberly, Demaria Rebecca, Yehuda Rachel

机构信息

Department of Psychiatry, James J. Peters VA Medical Center, Bronx, NY 10468, USA.

出版信息

Depress Res Treat. 2012;2012:393251. doi: 10.1155/2012/393251. Epub 2012 Apr 24.

DOI:10.1155/2012/393251
PMID:22611490
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3348629/
Abstract

Background. We obtained pilot data to examine the clinical and neuroendocrine effects of short-term mifepristone treatment in male veterans with PTSD. Methods. Eight male veterans with military-related PTSD completed a randomized, double-blind trial of one week of treatment with mifepristone (600 mg/day) or placebo. The primary clinical outcome measures were improvement in PTSD symptoms and dichotomously defined clinical responder status as measured by the CAPS at one-month follow-up. Additional outcome measures included self-reported measures of PTSD symptom severity, CAPS-2 symptom subscale scores, and morning plasma cortisol and ACTH levels. Results. Mifepristone was associated with significant improvements in total CAPS-2 score. At one-month follow-up, all four veterans in the mifepristone group and one of four veterans in the placebo group achieved clinical response; three of four veterans in the mifepristone group and one of four veterans in the mifepristone group remitted. Mifepristone treatment was associated with acute increases in cortisol and ACTH levels and decreases in cytosolic glucocorticoid receptor number in lymphocytes. Conclusions. Further controlled trials of the effects of mifepristone and their durability are indicated in PTSD. If effective, a short-term pharmacological treatment in PTSD could have myriad uses.

摘要

背景。我们获取了试点数据,以研究短期米非司酮治疗对患有创伤后应激障碍(PTSD)的男性退伍军人的临床和神经内分泌影响。方法。八名患有与军事相关PTSD的男性退伍军人完成了一项随机双盲试验,接受为期一周的米非司酮(600毫克/天)或安慰剂治疗。主要临床结局指标为PTSD症状的改善情况以及在1个月随访时通过临床医师专用PTSD量表(CAPS)测量的二分法定义的临床反应者状态。其他结局指标包括PTSD症状严重程度的自我报告测量、CAPS-2症状子量表得分以及早晨血浆皮质醇和促肾上腺皮质激素(ACTH)水平。结果。米非司酮与CAPS-2总分的显著改善相关。在1个月随访时,米非司酮组的所有四名退伍军人和安慰剂组的四名退伍军人中的一名实现了临床反应;米非司酮组的四名退伍军人中的三名和米非司酮组的四名退伍军人中的一名症状缓解。米非司酮治疗与皮质醇和ACTH水平的急性升高以及淋巴细胞中细胞溶质糖皮质激素受体数量的减少有关。结论。表明需要对米非司酮的作用及其持久性进行进一步的对照试验。如果有效,PTSD的短期药物治疗可能有多种用途。

相似文献

1
A Pilot Study of Mifepristone in Combat-Related PTSD.米非司酮治疗与战斗相关创伤后应激障碍的初步研究。
Depress Res Treat. 2012;2012:393251. doi: 10.1155/2012/393251. Epub 2012 Apr 24.
2
Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder: A Phase 2a Randomized Clinical Trial.米非司酮治疗男性美国退伍军人创伤后应激障碍的疗效和安全性:一项 2a 期随机临床试验。
JAMA Netw Open. 2023 May 1;6(5):e2310223. doi: 10.1001/jamanetworkopen.2023.10223.
3
A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.一项关于米非司酮治疗患有慢性多症状疾病的海湾战争退伍军人的随机、双盲、安慰剂对照、交叉试验。
Psychoneuroendocrinology. 2016 Feb;64:22-30. doi: 10.1016/j.psyneuen.2015.11.001. Epub 2015 Nov 10.
4
Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder.舍曲林治疗创伤后应激障碍退伍军人的双盲安慰剂对照初步研究。
J Clin Psychopharmacol. 2002 Apr;22(2):190-5. doi: 10.1097/00004714-200204000-00013.
5
Sleep disturbance in chronic military-related PTSD: clinical impact and response to adjunctive risperidone in the Veterans Affairs cooperative study #504.慢性军事相关创伤后应激障碍中的睡眠障碍:临床影响及在退伍军人事务部合作研究504中对辅助使用利培酮的反应
J Clin Psychiatry. 2016 Apr;77(4):483-91. doi: 10.4088/JCP.14m09585.
6
A pilot randomized placebo-controlled trial of adjunctive aripiprazole for chronic PTSD in US military Veterans resistant to antidepressant treatment.一项针对对抗抑郁治疗耐药的美国退伍军人慢性创伤后应激障碍(PTSD),使用阿立哌唑作为辅助治疗的随机安慰剂对照试验。
Int Clin Psychopharmacol. 2015 May;30(3):167-74. doi: 10.1097/YIC.0000000000000061.
7
Cortisol augmentation of a psychological treatment for warfighters with posttraumatic stress disorder: Randomized trial showing improved treatment retention and outcome.皮质醇增强心理治疗对患有创伤后应激障碍的战士的疗效:随机试验表明治疗依从性和治疗效果得到改善。
Psychoneuroendocrinology. 2015 Jan;51:589-97. doi: 10.1016/j.psyneuen.2014.08.004. Epub 2014 Aug 13.
8
3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.3,4-亚甲基二氧甲基苯丙胺(摇头丸)辅助心理治疗退伍军人、消防员和警察创伤后应激障碍:一项随机、双盲、剂量反应、2期临床试验。
Lancet Psychiatry. 2018 Jun;5(6):486-497. doi: 10.1016/S2215-0366(18)30135-4. Epub 2018 May 1.
9
Individual Treatment of Posttraumatic Stress Disorder Using Mantram Repetition: A Randomized Clinical Trial.个体创伤后应激障碍的曼特拉重复治疗:一项随机临床试验。
Am J Psychiatry. 2018 Oct 1;175(10):979-988. doi: 10.1176/appi.ajp.2018.17060611. Epub 2018 Jun 20.
10
Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.米非司酮血药浓度及糖皮质激素受体拮抗作用与精神病性抑郁症患者的反应相关
J Clin Psychopharmacol. 2017 Oct;37(5):505-511. doi: 10.1097/JCP.0000000000000744.

引用本文的文献

1
Recent Alcohol Use Influences Associations between Cortisol Levels and Negative Affect: The New Orleans Alcohol Use in HIV Study.近期饮酒对皮质醇水平与消极情绪之间关联的影响:新奥尔良HIV人群饮酒情况研究
AIDS Behav. 2025 Jul 7. doi: 10.1007/s10461-025-04815-7.
2
Three Prospective Case Studies Examining Mifepristone's Efficacy in Patients with Treatment-Resistant PTSD.三项前瞻性案例研究,考察米非司酮在难治性创伤后应激障碍患者中的疗效。
Case Rep Psychiatry. 2024 Apr 26;2024:4768647. doi: 10.1155/2024/4768647. eCollection 2024.
3
Post-traumatic stress disorder: a psychiatric disorder requiring urgent attention.创伤后应激障碍:一种需要紧急关注的精神障碍。
Med Rev (2021). 2022 Aug 2;2(3):219-243. doi: 10.1515/mr-2022-0012. eCollection 2022 Jun.
4
Efficacy and Safety of Mifepristone in the Treatment of Male US Veterans With Posttraumatic Stress Disorder: A Phase 2a Randomized Clinical Trial.米非司酮治疗男性美国退伍军人创伤后应激障碍的疗效和安全性:一项 2a 期随机临床试验。
JAMA Netw Open. 2023 May 1;6(5):e2310223. doi: 10.1001/jamanetworkopen.2023.10223.
5
Treatment of Posttraumatic Stress Disorder: A State-of-the-art Review.创伤后应激障碍的治疗:最新综述。
Curr Neuropharmacol. 2024;22(4):557-635. doi: 10.2174/1570159X21666230428091433.
6
Modeling gene × environment interactions in PTSD using human neurons reveals diagnosis-specific glucocorticoid-induced gene expression.使用人类神经元对 PTSD 中的基因×环境相互作用进行建模揭示了特定于诊断的糖皮质激素诱导的基因表达。
Nat Neurosci. 2022 Nov;25(11):1434-1445. doi: 10.1038/s41593-022-01161-y. Epub 2022 Oct 20.
7
Pharmacological Implications of Adjusting Abnormal Fear Memory: Towards the Treatment of Post-Traumatic Stress Disorder.调节异常恐惧记忆的药理学意义:迈向创伤后应激障碍的治疗
Pharmaceuticals (Basel). 2022 Jun 24;15(7):788. doi: 10.3390/ph15070788.
8
Effects of RU486 in Treatment of Traumatic Stress-Induced Glucocorticoid Dysregulation and Fear-Related Abnormalities: Early versus Late Intervention.RU486 治疗创伤后应激导致的糖皮质激素失调和恐惧相关异常的效果:早期与晚期干预。
Int J Mol Sci. 2022 May 14;23(10):5494. doi: 10.3390/ijms23105494.
9
Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches.创伤后应激障碍的药物治疗:单药治疗、增效治疗和头对头治疗的系统评价和荟萃分析。
Eur J Psychotraumatol. 2021 Jan 26;12(1):1802920. doi: 10.1080/20008198.2020.1802920. eCollection 2021.
10
Translating Molecular and Neuroendocrine Findings in Posttraumatic Stress Disorder and Resilience to Novel Therapies.创伤后应激障碍的分子和神经内分泌研究与新疗法的抗性
Biol Psychiatry. 2019 Sep 15;86(6):454-463. doi: 10.1016/j.biopsych.2019.07.009. Epub 2019 Jul 24.

本文引用的文献

1
Systemic and intrahippocampal administrations of the glucocorticoid receptor antagonist RU38486 impairs fear memory reconsolidation in rats.系统和海马内给予糖皮质激素受体拮抗剂 RU38486 可损害大鼠的恐惧记忆再巩固。
Stress. 2011 Jul;14(4):459-64. doi: 10.3109/10253890.2010.548171. Epub 2011 Mar 27.
2
Mifepristone (RU486) restores humoral and T cell-mediated immune response in endotoxin immunosuppressed mice.米非司酮(RU486)可恢复内毒素免疫抑制小鼠的体液和 T 细胞介导的免疫应答。
Clin Exp Immunol. 2010 Dec;162(3):568-77. doi: 10.1111/j.1365-2249.2010.04262.x. Epub 2010 Oct 21.
3
The acute and post-discontinuation effects of a glucocorticoid receptor (GR) antagonist probe on sleep and the HPA axis in chronic insomnia: a pilot study.糖皮质激素受体(GR)拮抗剂探针对慢性失眠患者睡眠和下丘脑-垂体-肾上腺(HPA)轴的急性及停药后效应:一项初步研究。
J Clin Sleep Med. 2008 Jun 15;4(3):235-41.
4
Mifepristone versus placebo in the treatment of psychosis in patients with psychotic major depression.米非司酮与安慰剂治疗伴有精神病性症状的重度抑郁症患者的精神病症状对比研究
Biol Psychiatry. 2006 Dec 15;60(12):1343-9. doi: 10.1016/j.biopsych.2006.05.034. Epub 2006 Aug 4.
5
Effects of adjunctive mifepristone (RU-486) administration on neurocognitive function and symptoms in schizophrenia.辅助使用米非司酮(RU-486)对精神分裂症神经认知功能及症状的影响。
Biol Psychiatry. 2005 Jan 15;57(2):155-61. doi: 10.1016/j.biopsych.2004.10.017.
6
Enhanced sensitivity to glucocorticoids in peripheral mononuclear leukocytes in posttraumatic stress disorder.创伤后应激障碍患者外周血单个核白细胞对糖皮质激素的敏感性增强。
Biol Psychiatry. 2004 Jun 1;55(11):1110-6. doi: 10.1016/j.biopsych.2004.02.010.
7
Improvements in neurocognitive function and mood following adjunctive treatment with mifepristone (RU-486) in bipolar disorder.米非司酮(RU - 486)辅助治疗双相情感障碍后神经认知功能和情绪的改善。
Neuropsychopharmacology. 2004 Aug;29(8):1538-45. doi: 10.1038/sj.npp.1300471.
8
An open label trial of C-1073 (mifepristone) for psychotic major depression.一项关于C-1073(米非司酮)治疗重度抑郁伴精神病性症状的开放标签试验。
Biol Psychiatry. 2002 Sep 1;52(5):386-92. doi: 10.1016/s0006-3223(02)01432-4.
9
Mifepristone: bioavailability, pharmacokinetics and use-effectiveness.米非司酮:生物利用度、药代动力学及使用效果
Eur J Obstet Gynecol Reprod Biol. 2002 Mar 10;101(2):113-20. doi: 10.1016/s0301-2115(01)00522-x.
10
Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder.创伤后应激障碍退伍军人的脑脊液促肾上腺皮质激素释放激素水平及肾上腺皮质活动的系列研究
Am J Psychiatry. 1999 Apr;156(4):585-8. doi: 10.1176/ajp.156.4.585.